Showing results (311-320 of 330) with videos related to

Sort By:
Pageof 33
Journal of Diabetes Investigation|May 21, 2014
Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobinHye Soo Chung, Sunghwan Suh, Mi Yeon Kim, et al.
Biosensors & Bioelectronics|December 23, 2025
High-performance graphene field-effect transistor platform for on-site schizophrenia-related biomarkers detectionSeo Jin Kim, Yeon Kyung Cha, Kyung Ho Kim, et al.
Diabetes & Metabolism Journal|December 15, 2025
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic DrugsJun Hwa Hong, Kyung Wan Min, Chang Beom Lee, et al.
Biomaterials|June 2, 2019
Multi-layer surface modification of pancreatic islets for magnetic resonance imaging using ferumoxytolSang-Man Jin, Han Sin Lee, Muhammad R Haque, et al.
Diabetes & Metabolism Journal|November 8, 2013
Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1cJa Young Jeon, Seung-Hyun Ko, Hyuk-Sang Kwon, et al.
Diabetes, Obesity & Metabolism|March 1, 2024
A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozinSoo Lim, Seung-Hwan Lee, Kyung-Wan Min, et al.
Plos One|July 28, 2017
Subclinical thyroid dysfunction and risk of carotid atherosclerosisHosu Kim, Tae Hyuk Kim, Hye In Kim, et al.
Diabetologia|April 18, 2024
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trialJi Yoon Kim, Sang-Man Jin, Eun Seok Kang, et al.
Nature Communications|January 9, 2021
An autophagy enhancer ameliorates diabetes of human IAPP-transgenic mice through clearance of amyloidogenic oligomerJinyoung Kim, Kihyoun Park, Min Jung Kim, et al.
Diabetes, Obesity & Metabolism|October 8, 2024
Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III studyJun Hwa Hong, Myung Jin Kim, Kyung Wan Min, et al.
Pageof 33